ticagrelor + clopidogrel

ApprovedTerminated
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Non-ST Elevation Acute Coronary Syndrome

Conditions

Non-ST Elevation Acute Coronary Syndrome

Trial Timeline

Sep 1, 2014 → Apr 1, 2015

About ticagrelor + clopidogrel

ticagrelor + clopidogrel is a approved stage product being developed by AstraZeneca for Non-ST Elevation Acute Coronary Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT02052635. Target conditions include Non-ST Elevation Acute Coronary Syndrome.

What happened to similar drugs?

1 of 2 similar drugs in Non-ST Elevation Acute Coronary Syndrome were approved

Approved (1) Terminated (0) Active (1)
Ticagrelor + ClopidogrelAstraZenecaApproved
🔄Tirofiban + TicagrelorAstraZenecaPhase 3

Hype Score Breakdown

Clinical
20
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (20)

NCT IDPhaseStatus
NCT04069234Phase 3Withdrawn
NCT03437044ApprovedCompleted
NCT02617290Phase 3Completed
NCT02663713ApprovedCompleted
NCT02319941Phase 2Completed
NCT02457130ApprovedUNKNOWN
NCT02379676ApprovedUNKNOWN
NCT02121288ApprovedWithdrawn
NCT02233790ApprovedUNKNOWN
NCT02618733Pre-clinicalCompleted
NCT02052635ApprovedTerminated
NCT01826175ApprovedWithdrawn
NCT01864005ApprovedCompleted
NCT01732822Phase 3Completed
NCT01706510ApprovedCompleted
NCT01603082ApprovedCompleted
NCT01523366ApprovedCompleted
NCT01523392ApprovedCompleted
NCT01118325Phase 2Completed
NCT00391872Phase 3Completed

Competing Products

2 competing products in Non-ST Elevation Acute Coronary Syndrome

See all competitors
ProductCompanyStageHype Score
Tirofiban + TicagrelorAstraZenecaPhase 3
36
Ticagrelor + ClopidogrelAstraZenecaApproved
43